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bjectives The objectives of this study were: 1) to delineate the temporal course of histopathologic
ealing as the left atrial appendage (LAA) is obliterated by a mechanical device; and 2) to compare
his process with other intravascular and intracardiac implanted technologies.
ackground Intracardiac device healing is incompletely understood. We thus studied the histopa-
hology of device-based LAA obliteration.
ethods Nine dog hearts were examined over time after LAA device placement and results were
ompared with human hearts with prior LAA obliteration using the same device.
esults At 3 days in dogs, atrial surfaces were covered by ﬁbrin, which sealed gaps between the
A wall and the device and ﬁlled the LA appendage cavity. At 45 days, endothelial cells covered the
ndocardial surface with underlying smooth muscle cells that sealed the device-LA interface. Re-
ions with prior thrombus were replaced by endocardium surrounding the device membrane. Disor-
anized thrombus remained in the LAA body and at the periphery near the appendage walls. Mild
nﬂammation was observed as thrombus resorbed. By 90 days, a complete endocardial lining cov-
red the former LAA ostium. Organizing thrombus had become connective tissue, with no residual
nﬂammation. The human necropsy hearts had similar ﬁndings. In these 4 hearts (139, 200, 480, and
52 days after implant), the ostial fabric membrane was covered with endocardium. The appendage
urface contained organizing thrombus with minimal inﬂammation. Organizing ﬁbrous tissue was inside
he LAA cavity, prominent near the atrial wall. The LAA interior contained organizing thrombus.
onclusions This intracardiac device integration study delineated healing stages of early thrombus
eposition, thrombus organization, inﬂammation and granulation tissue, ﬁnal healing by connective
issue, and endocardialization without inﬂammation. These observations may yield insight into cellu-
ar healing processes in other cardiac devices. (J Am Coll Cardiol Intv 2010;3:870–7) © 2010 by the
merican College of Cardiology Foundation
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871he histopathologic healing and integration of implantable
ntracardiac devices is incompletely characterized (1,2).
cattered reports document the healing of heart valves (3–6)
nd atrial septal occluders (7–9) but do not put these
rocesses into a larger context, especially because such
rocesses may be similar to stent healing in coronary arteries
10–13). Because many new intracardiac devices for struc-
ural heart disease are undergoing clinical evaluation (e.g.,
trial septal defect, patent foramen ovale closure), a com-
arative description of device healing could provide a useful
omparison. This study thus examined the healing histopa-
hology of a device designed to obliterate the left atrial
ppendage (LAA) using a fabric membrane covering mul-
iple metal support struts (Fig. 1). The study specifically
ought to evaluate the device-tissue interface of the
atchman (Atritech, Inc., Plymouth, Minnesota) after
ercutaneous, permanent implant into the body of the
AA, with especial interest dealing with both safety and
fficacy (14 –18).
ethods
he study was approved by the Institutional Animal Care
nd Use Committee of the University of Minnesota and
onformed to the position of the American Heart Associ-
tion on use of animals in research.
Watchman LAA obliteration devices were implanted in
he LAA of 9 dogs via surgical open visualization using
horacotomy and a venous transseptal method. Femoral
enous access was obtained via intravascular sheath. Under
uoroscopic visualization, devices were placed in the LAA
ia transseptal approach. A left fourth- or fifth-intercostal
pace thoracotomy was also performed to directly observe
he implant. Post-operatively, a thoracotomy tube was
laced and connected to a water-sealed chest drain. The
horacotomy tube was removed when the dog was stable and
pontaneously breathing.
Cephalexin 30 mg/kg was administered intramuscularly
ithin 24 h of the procedure and continued twice daily for
days post-operatively. Gentamicin 3 mg/kg was given
ntravenously within 24 h of surgery and on the day of
urgery. Aspirin 325 mg was given orally twice daily on
he day of surgery and then once daily for the duration of
he study. One day before the procedure, warfarin 6
g/day was given orally and continued until euthanasia.
his warfarin regimen was implemented in dogs to
imic a program expected in the human clinical trials
hat were planned to follow the pre-clinical dog studies,
ncluding the chronic time points.
The animals were euthanized in 3 groups at different time
oints: 3 animals at 3 days following implant (Group I), 3
nimals at 45 days (Group II), and 3 animals at 90 days
Group III). Euthanasia was accomplished immediately
fter final fluoroscopic imaging. Animals were heparinized tnd death was induced by lethal intravenous doses of a
ommercial solution (Beuthanasia, Schering-Plough, Kenil-
orth, New Jersey). After euthanasia, pathologic and his-
opathologic analysis was performed via standard methods.
At necropsy, the kidneys, livers, spleens, and lungs were
nspected for evidence of infarction or other pathology.
ollowing this, the hearts, lungs, livers, spleens, and the
idneys were immersion-fixed in 10% neutral buffered
ormalin for 48 h. Devices were evaluated for positioning,
ompleteness of seal, penetration of struts, atrial appendage
istention, and appearance of the atrial prosthetic device
urface. The LAA, device, and the adjacent atrial wall were
ehydrated in a graded series of ethanol and embedded in
ethyl methacrylate plastic. After polymerization of the
lastic, 3 to 4 equidistant longitudinal sections approxi-
ately 0.5 cm in thickness were sawed through the device
nd the atrial appendage and wall. The sections were ground
o a thickness of 40 to 50 m using Exakt Linear Grinding
Exakt Medical Instruments, Oklahoma City, Oklahoma)
echnology, polished, and stained with toluidine blue and
asic fuchsin stains. All sections were examined by light
icroscopy for inflammation, thrombus, neointimal forma-
ion, endothelialization, LAA obliteration, and device seal-
ng of the LAA. Atrial appendage histopathology was
xamined with special attention
o the atrial surface and to eval-
ate the tissue response sur-
ounding and within the device.
Four human hearts with de-
ices were also available for
tudy. In each case, the patients died of causes unrelated to
he device or procedure. In these patients, the anticoagula-
ion regime was warfarin after implant that was then
iscontinued on day 45. Hearts were obtained from patients
ying at 39, 200, 480, and 852 days after implantation. All
earts were examined grossly before embedding in methyl
ethacrylate plastic.
esults
ll dog implants were performed successfully without com-
lication. Devices were appropriately placed within the
AA, beyond the appendage/atrial ostium. There was no
ross or microscopic evidence of infarction in any of the
rgans including the heart in all animals, suggesting no
ignificant embolization to these organs. There was no
vidence of trauma to the underlying left circumflex coro-
ary artery in all 9 hearts.
og Group I: 3 days. One early death occurred in Group I
n the day the animal was to be euthanized. Autopsy
valuation revealed an intrathoracic hemorrhage that origi-
ated from the area of the left internal mammary artery near
Abbreviations
and Acronyms
LAA  left atrial appendagehe thoracotomy site. There was no hemopericardium, and
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872subcutaneous hematoma in the left thorax and abdomen
uggested that hemorrhage did not occur from the heart.
his was thus considered a procedural- rather than a
evice-related death.
In all cases, before removal of the heart, the pericardium
ould be easily separated from the heart surface, as only a
ild pericarditis was evident. This mild pericarditis was
ocal only. The late groups showed no apparent effects of
hronic pericarditis.
All devices in Group I could be easily removed from the
AA. Consistent accumulation of organizing thrombus
overed the prosthetic device atrial surface and was of
ariable thickness (Fig. 2). A neutrophilic infiltrate was
requently observed, with the organizing thrombus also
howing some macrophages. The myocardium at the junc-
ion of the implant showed focal necrosis likely due to the
truts and fabric pressure creating compression atrophy.
erforation of 2 wires through the epicardium was seen in 1
mplant, but without apparent consequence. The wires were
ot broken. The inner lumen of the device was filled with
cute thrombus in only 1 device, whereas the other 2
Figure 1. Composite Images of the LAA and Obliteration
(A) Post-mortem dog heart (no device implanted), showing the exterior view o
obliteration method. Metal struts with anchoring hooks secure the device with
surface of the device, preventing thrombi from escaping into the left atrial
system. (C) Dog autopsy specimen 28 days after Watchman implant showin
brane is covered with a ﬁne layer of endocardium, and the metal struts are sh
are labeled. (D) Dog autopsy specimen showing a view of the former LAA
brane. This view is from the left atrial cavity, where it is clear that thrombi
into the left atrium and systemic circulation.howed partial filling. uog Group II: 45 days. The fabric membrane of the
rosthetic device at the LAA opening had an organized
eoendocardial surface. The glistening white pannus on
he atrial surface of the device was thin, but was substan-
ially thicker beneath the membrane, on the LAA side. It
lso showed an extension of the ingrowth into the LA
all surface (Figs. 3 and 4). A moderate granulomatous
nflammation occurred near the woven material. His-
opathologic examination showed it was granulation
issue lined by a thin layer of endothelial-like cells.
ndocardial ingrowth completely covered all exposed
urfaces and was continuous with the LA surface, which
esulted in effectively sealing the device-LA interface.
rior fibrin deposition had been replaced by an endocar-
ium, which consisted of smooth muscle cells in a
roteoglycan-collagenous matrix that surrounded the
etal and fabric elements (Fig. 3).
og Group III: 90 days. In Group III, fibrous tissue pannus
ncapsulated the woven fabric on the prosthetic atrial wall.
he fibroblastic response was accompanied by none or a
ild inflammatory response with occasional chronic gran-
left atrial appendage (LAA). (B) Diagrammatic view of the Watchman LAA
body of the appendage cavity. A fabric membrane ﬁlter covers the atrial
ber. A center hub is used to connect the device to the catheter delivery
ross-sectional cutaway view of the Watchman device. The fabric mem-
olding the device in place. Pectinate muscles internal to the LAA cavity
, now completely obliterated by the endocardium-covered fabric mem-
tially residing the left atrial appendage body could no longer escapef the
in the
cham
g a c
own h
ostium
potenlomatous reaction. The tissue had a monolayer of
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873ndothelial-like cells covering a healthy neoendocardium,
hich consisted of smooth muscle cells in a collagenous
atrix. The woven fabric and metallic center of the device
ere visible due to formation of a thin tissue covering at
hese sites.
Widely organized chronic thrombus within the atrial
ppendage device showed significant angiogenesis in
roups II and III. Two animals (1 each from Groups II and
II) had an empty lumen in the distal part of the LAA
evice, and the lumen was lined by a collagenous capsule. In
animals, a communication occurred between the pectinate
trial muscle and the distal part of the appendage. This
ommunication was small, and the body of the appendage
as filled with healing fibrotic tissue.
The temporal changes in the 90-day dog group in
omparison to the 45-day group are principally those of
ontinued healing, with continued resorption of the
hrombus mass trapped in the obliterated appendage
ithin the device, and continued replacement with col-
Figure 2. Dog Heart 72 H After Device Implantation
(A) Postmortem in vitro X-ray showing position of the left atrial appendage ob
brane (arrow) is coated with a thin layer of ﬁbrin. (C,D) Methyl methacrylate–
and ﬁbrinous sealing of the membrane to the left atrial wall (white arrow).agen and pannus. tAt all time points, search for emboli via pathology
howed no evidence of acute or chronic emboli to the
oronary arteries or brain.
uman hearts. Four human hearts with prior device im-
lant were available for review. Causes of death were
nrelated to the device. Gross and histopathologic findings
n these hearts were similar to those in Group III of the
ogs. In these hearts (139, 200, 480, and 852 days following
mplant), the fabric membrane showed varying coverage
ith organized endocardium (Figs. 4 and 5). Two devices
howed an early organizing, thin laminar fibrin thrombus
overing most of each device’s atrial surface. Neither of the
xterior thrombi had substantive mass, and neither looked
rittle or fragile. Organized neoendocardial growth sealed
he interfaces of each device and native appendage wall. The
hird and fourth devices showed an organizing endocardial
rowth covering approximately 85% to 90% of each device’s
urface, which was thicker near the appendage wall inter-
ace. The overgrowth contained well-organized collagen
ion device (arrow). (B) Gross photograph showing that the device mem-
dded sections showing thin ﬁbrin coating on the membrane (black arrow)literat
embehat was continuous with the native appendage wall. An
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874ndothelial cell monolayer lined the neoendocardium near
he LAA/luminal interface though there was no appreciable
ndothelial coverage over the center of each device. On each
evice’s undersurface (appendage cavity side), an organizing
hrombus covered the membrane, without significant in-
ammation at the strut or fabric site. Organizing fibrous
issue was seen inside the LAA in varying degrees, promi-
ent at and near the atrial wall. Each device’s interior
ontained red blood cells and organizing fibrin thrombus,
imilar to that observed in the pre-clinical studies. The inner
ip of the appendage of the 852-day implant showed blood
lled trabecular spaces possibly fed by collateral circulation
rom the appendage wall.
The variability in organized neoendocardial coverage over
he devices was possibly due to placement within the
ppendage. Healing reactions were similar between animals
nd humans, but animal healing was faster.
iscussion
his study describes device healing after LAA obliteration
ver time from a histopathologic and macroscopic perspec-
Figure 3. Dog Heart, 45 Days After Device Implantation
(A) A glistening white pannus covers the left atrial surface of the device (arro
device (arrows), effectively locking the device in place and preventing exit of
chamber. (C) The interface between the device membrane and the left atrial w
thin on the atrial chamber surface but was substantially thicker beneath the m
rior of the left atrial appendage device. The white arrow points to, and is with
whole blood trapped within the appendage after device placement.ive. Results in dogs and patients were similar to an earlier levice that did not complete large-scale development (Per-
utaneous Left Atrial Appendage Transcatheter Occlusions
PLAATO] device, ev3, Plymouth, Minnesota) (19,20).
he Watchman LAA device implant caused mild distention
nd atrial appendage expansion, with mild LA epicarditis
nd no significant pericarditis. Early sealing was partial to
omplete, and the interior of the LAA subsequently filled
ith thrombus in most cases that eventually organized.
he angiogenesis found within the organizing appendage
hrombus and its communication with pectinate append-
ge muscle in the distal part of the appendage likely have
o clinical findings, because this anatomic occurrence is
ithin the obliterated portion of the appendage body.
The LA surface of the device became covered with a new
ndocardium (observed in all 4 patients), including 1 at the
arliest human time point of 139 days. This neoendocar-
ium occurred over the prosthetic atrial device surface and
as probably the result of organization of a fibrin-rich thin
ayer of thrombus, through granulation tissue with eventual
eplacement by smooth muscle cells in a proteoglycan-
ollagen matrix and endothelialization.
The canine species has substantial variability in LAA
) The neoendocardial covering is continuous from the left atrial wall to the
sidual thrombus from the interior of the obliterated left atrial appendage
completely sealed by ﬁbrous tissue (arrow). (D) The neoendocardium was
ane (black arrow). Dense, organized ﬁbrin is being resorbed from the inte-
large region of organizing thrombus. This thrombus is coagulation of thew). (B
any re
all is
embr
in, aobular structure, as do humans. This likely influences the
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875ealing in only a minor way, because the majority of healing
ccurs at the LAA ostium rather than in the recesses of the
ppendage body. The continuity of histopathologic healing
ith LAA obliteration and with other intracardiac devices
uch as valves is apparent. For example, healing after
urgical injury to mitral valves was studied in sheep by
amura et al. (4). An in vitro study (5) showed that
ultilayered endocardial cells cover wounded regions early,
ithin 4 to 6 days. Endocardial layers consist of endothe-
ium and coalesced myofibroblasts growing within the
ranulation tissue that forms after thrombus deposition. van
en Brand et al. (21) showed young scar tissue occurring at
njury sites of the aortic valve following valvuloplasty as late
s 24 months, also accompanied by mature fibrous tissue.
Interestingly, the Watchman LAA obliteration device
eals comparably in both dogs and humans through a
rocess similar to intracoronary stents: a fibrin-rich throm-
us that organizes by an inflammatory granulation tissue
eaction, followed by pannus formation consisting of
mooth muscle cells in a proteoglycan-collagenous matrix
nd surface endothelialization with continued thrombus
Figure 4. Human Heart 200 Days After Implantation
(A) Opened left atrium showing the device seated within the appendage oriﬁc
and the edge of the appendage ostium margin (arrows), though the appenda
thrombi could form nor exit this appendage. (B) Sagittal section through the c
device to the appendage wall and sealing of the device-appendage wall interf
ine blue and basic fuchsin stain. (C) Close-up view through the center of the d
fuchsin stain, 1.25. (D) Close-up view of the device surface showing effective
siderin resulting from red cell breakdown. Toluidine blue and basic fuchsin staesorption (10,13,22,23). sSafety and efficacy of the LAA obliteration as related to
istopathology entails several considerations. The device
rocess appeared safe in that no macroscopic thrombus of
ny sort (loose or attached) was found on the fabric
embrane at the observed time points. Fibrin on the
embrane was thin and laminar, covering and becoming
art of the membrane. Even though the human pathology
ata showed that 85% to 90% of the surface was covered by
ndothelium, this likely has little influence as evidenced by
he PROTECT-AF (Watchman Left Atrial Appendage
ystem for Embolic Protection in Patients With Atrial
ibrillation) clinical trial that showed 32% fewer clinical
vents in the device-treated group versus the warfarin-only
reated group (24).
Efficacy can be estimated by observing the device sealing off
he appendage ostium. The device edges showed tissue conti-
uity with the appendage ostium in all cases, leaving neither
paces nor other mechanism residual appendage body contents
o exit the appendage cavity. The device similarly integrated
nto the wall, so that it could not itself embolize.
Healing of blood-containing organs and blood-contacting
re are small linear gaps between the concave surface of the device fabric
vity behind the covered membrane was healing with endocardium so no
of the appendage and device. The section shows tight apposition of the
side the device, the reddish-pink areas indicate ﬁbrous organization. Toluid-
showing neointimal coverage over the surface. Toluidine blue and basic
g of the atrial wall-device interface (arrow). Brown areas represent hemo-
.e. The
ge ca
enter
ace. In
evice
sealinurfaces is a fundamental biologic process because reliable
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876nd rapid cellular function is imperative to species sur-
ival. This study confirmed continuity of such key healing
rocesses across species (humans and dogs), devices
cardiac valves, LAA occluders, and vascular stents), and
natomic location (intracardiac and intra-arterial), sug-
esting a universal and fundamental set of cellular events.
or example, Hara et al. (25) showed a very similar result
or patent foramen ovale closure healing with a
adiofrequency-based welding to shut the patent foramen
vale membranes. Two other papers (9,26) describe
ntimal tissue formation in atrial septal defect occlusion
evices, showing progressive diminution of macrophages,
nd fibroblast growth with maturation over a 10-week
eriod.
These healing events begin with fibrin-thrombus depo-
ition (initially unorganized, later dense and organized),
ollowed by controlled inflammation consisting of macro-
hages and lymphocytes resorbing the thrombus. Smooth
uscle cell infiltration and fibrous tissue generation then
ead to endothelial coverage resembling the endocardium
hat develops a final, biocompatible blood-contacting
nterface. These events, when understood, may prove
Figure 5. Human Heart 852 Days After Implantation
(A) Atrial view of a human heart, showing the left atrial appendage ostium ob
device is indicated by the red arrow. Black arrows show the lip of the forme
interface. (B) Sagittal section through the center of the appendage and device
sealing of the device–appendage wall interface (arrows). Inside of the device,
for orientation of high-power view shown in (D). This is the left atrial surface.
dial layer covering the surface near the center of the device. Toluidine blue anseful for designing new technologies or enhancingiocompatibility of older devices for intracardiac and
ntravascular application.
tudy limitations. There are several important limitations to
his study. The dog studies showed faster healing than the
atients did, though the histopathology was comparable
lbeit on a different time scale.
The duration of warfarin therapy was chronic in the dogs,
hough shorter in the patients. The impact is uncertain,
hough there was congruence between human and animal
istopathology regarding thrombus on the device mem-
rane. The implications of healing in the animal study with
espect to warfarin therapy in the dogs are principally that of
iming, as has been true with coronary stents. However, this
ay be beneficial, with animal models showing the healing
n a shorter time scale. The human healing time course
ppears to be compressed in the animal model.
eprint requests and correspondence: Dr. Robert S. Schwartz,
inneapolis Heart Institute and Minneapolis Heart Institute
oundation, 920 East 28th Street, Suite 620, Minneapolis, Min-
esota 55407. E-mail: rss@rsschwartz.com.
ed by the implanted device, 852 days after implantation. The center of the
m, now obliterated. Residual post-mortem blood is seen at the device-atrial
section showed tight apposition of the device to the appendage wall and
ddish-pink areas indicated early ﬁbrous organization. (C) Low-power view
ose-up view of the left atrial device surface showing an organized endocar-
ic fuchsin stain.literat
r ostiu
. The
the re
(D) Cl
R1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
K
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 8 , 2 0 1 0 Schwartz et al.
A U G U S T 2 0 1 0 : 8 7 0 – 7 Healing Stages of Intracardiac Devices
877EFERENCES
1. Brais M, Braunwald NS. Acceleration of tissue ingrowth on materials
implanted in the heart. Ann Thorac Surg 1976;21:221–9.
2. Little K. Mechanisms of incorporation of homografts and heterografts.
Proc R Soc Med 1970;63:999–1002.
3. Kim WG, Sung K, Seo JW. Time-related histopathologic analyses of
immunologically untreated porcine valved conduits implanted in a
porcine-to-goat model. Artif Organs 2007;31:105–13.
4. Tamura K, Jones M, Yamada I, Ferrans VJ. Wound healing in the
mitral valve. J Heart Valve Dis 2000;9:53–63.
5. Lester WM, Gotlieb AI. In vitro repair of the wounded porcine mitral
valve. Circ Res 1988;62:833–45.
6. Lyons WS, Kirklin JW. Surgical healing of the atrioventricular leaflets:
an experimental study. Surg Forum 1957;8:387–9.
7. Kreutzer J, Ryan CA, Gauvreau K, Van Praagh R, Anderson JM,
Jenkins KJ. Healing response to the Clamshell device for closure of
intracardiac defects in humans. Catheter Cardiovasc Interv 2001;54:
101–11.
8. Lee TT, De la Torre R, Carrozza JP Jr. Suture-mediated closure of a
patent foramen ovale during surgery without cardiopulmonary bypass.
Catheter Cardiovasc Interv 2006;68:747–8.
9. Jux C, Bertram H, Wohlsein P, Bruegmann M, Paul T. Interventional
atrial septal defect closure using a totally bioresorbable occluder matrix:
development and preclinical evaluation of the BioSTAR device. J Am
Coll Cardiol 2006;48:161–9.
0. Nakazawa G, Finn AV, Virmani R. Vascular pathology of drug-eluting
stents. Herz 2007;32:274–80.
1. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in
humans: delayed healing and late thrombotic risk. J Am Coll Cardiol
2006;48:193–202.
2. Virmani R, Farb A, Guagliumi G, Kolodgie FD. Drug-eluting stents:
caution and concerns for long-term outcome. Coron Artery Dis
2004;15:313–8.
3. Schwartz RS, Henry TD. Pathophysiology of coronary artery resteno-
sis. Rev Cardiovasc Med 2002;3 Suppl 5:S4–9.
4. Lerakis S, Synetos A. Left atrial appendage exclusion system for stroke
prevention in atrial fibrillation: a percutaneous device delivery ap-
proach. Minerva Cardioangiol 2008;56:667–70.5. Chiam PT, Ruiz CE. Percutaneous transcatheter left atrial appendage
exclusion in atrial fibrillation. J Invasive Cardiol 2008;20:E109–13. a6. Cruz-Gonzalez I, Cubeddu RJ, Sanchez-Ledesma M, et al. Left atrial
appendage exclusion using an Amplatzer device. Int J Cardiol 2009;
134:e1–3.
7. Sick PB, Schuler G, Hauptmann KE, et al. Initial worldwide experi-
ence with the WATCHMAN left atrial appendage system for stroke
prevention in atrial fibrillation. J Am Coll Cardiol 2007;49:1490–5.
8. Bayard YL, Ostermayer SH, Sievert H. Transcatheter occlusion of the
left atrial appendage for stroke prevention. Expert Rev Cardiovasc Ther
2005;3:1003–8.
9. Nakai T, Lesh MD, Gerstenfeld EP, Virmani R, Jones R, Lee RJ.
Percutaneous left atrial appendage occlusion (PLAATO) for prevent-
ing cardioembolism: first experience in canine model. Circulation
2002;105:2217–22.
0. Park JW, Gerk U, Franke RP, Jung F. Post-mortem analysis of a left
atrial appendage occlusion device (PLAATO) in a patient with
permanent atrial fibrillation. Cardiology 2009;112:205–8.
1. van den Brand M, Essed CE, Di Mario C, et al. Histological changes
in the aortic valve after balloon dilatation: evidence for a delayed
healing process. Br Heart J 1992;67:445–9.
2. Nakazawa G, Ladich E, Finn AV, Virmani R. Pathophysiology of
vascular healing and stent mediated arterial injury. EuroIntervention
2008;4 Suppl C:C7–10.
3. Nakazawa G, Finn AV, Kolodgie FD, Virmani R. A review of current
devices and a look at new technology: drug-eluting stents. Expert Rev
Med Devices 2009;6:33–42.
4. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the
left atrial appendage versus warfarin therapy for prevention of stroke in
patients with atrial fibrillation: a randomised non-inferiority trial.
Lancet 2009;374:534–42.
5. Hara H, Jones TK, Ladich ER, et al. Patent foramen ovale closure by
radiofrequency thermal coaptation: first experience in the porcine
model and healing mechanisms over time. Circulation 2007;116:
648–53.
6. Foth R, Quentin T, Michel-Behnke I, et al. Immunohistochemical
characterization of neotissues and tissue reactions to septal defect-
occlusion devices. Circ Cardiovasc Interv 2009;2:90–6.
ey Words: atrial fibrillation  embolic stroke  left atrial
ppendage.
